CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 129 enrolled
Drug / intervention
Tdap vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03498300
NCT03498300Early Ph 1Completed
CompareCT.gov

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Pregnant Thai Women

Mahidol University·interventional·Posted Apr 13, 2018·Updated Mar 24, 2020

In Brief

A Early Phase 1 clinical trial evaluating Tdap vaccine for Pertussis and Pregnancy Related. Completed, enrolled 129 participants across 1 site.

Detailed Summary

This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women. All seronegative participants received Tdap, while seropositive participants were equally randomized into 2 groups. Half of seropositive participants received Tdap and the other half received tetanus-diphtheria (Td) as standard protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPertussis, Pregnancy Related
CountriesThailand
Collaborators--

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedApr 13, 2018
Enrollment StartMay 9, 2018
Primary CompletionApr 13, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.2 years ago

Interventions

Tdap vaccinebiological

A single dose of Tdap vaccine at GA 27 - 36 weeks